Recon: Weight-loss drugs take centerstage at ADA; GSK settles first US Zantac cancer suit ahead of trial

• U.S. Vaccine Program Now Flush With Cash, but Short on Key Details (NYTimes)
• Merck accused of downplaying early evidence of drug’s brain impact (Reuters)
• Pfizer scraps one weight loss drug in race to develop Ozempic rival (Reuters) (STAT)
• GSK soothes investors by settling first Zantac cancer lawsuit due for US trial (Reuters)
• UnitedHealth unit to add Boehringer's Humira biosimilar to reimbursement list (Reuters)
• US FDA approves Pfizer's hair loss drug (Reuters)
• Purdue Pharma can protect Sackler owners in opioid bankruptcy (Reuters)
• FDA issues draft guidance for clinical research into psychedelics (Endpoints)
• Jazz sues FDA, HHS over rival narcolepsy drug approval (Endpoints)
• How the Shortage of a $15 Cancer Drug Is Upending Treatment (NYTimes)
• The next big advance in cancer treatment could be a vaccine (AP)
• A Pill Form of Ozempic Is on the Horizon (NYTimes)
• STAT-Harris Poll: Nearly half of U.S. adults would spend $100 a month for Ozempic, other weight-loss drugs (STAT)

• Novo Nordisk says obesity pill leads to 15% weight loss; availability 'to be determined' (Reuters)
• Zealand, Boehringer tout higher weight-loss drug efficacy in update (Reuters)
• Galderma raises $1 bln through private placement before IPO (Reuters)
• iNova to buy Mundipharma's consumer healthcare brands for $540 mln (Reuters)
• EU poised to reject Amylyx’s ALS drug, as the company vows an appeal (STAT)
• COVID-19 vaccine scheme for poorest has $2.6bn left to spend as pandemic recedes (Reuters)
• Indonesia police probe drug regulators over cough syrup (Reuters)
• Teleflex, and Arrow International, Recall ARROW Endurance Extended Dwell Peripheral Catheter System for Risk of Catheter Separation and Leakage (GOV.UK)

• Biotech begins human trials of drug designed by artificial intelligence (FT)
• After steering Lundbeck through buyouts, layoffs and big approval, Deborah Dunsire will step down (Endpoints)
• WHO outlines 40 research priorities on antimicrobial resistance (WHO)
• 5 FDA decisions to watch in the third quarter (BioPharmaDive)
• In approving Sarepta's DMD gene therapy, FDA's Peter Marks overruled reviewers' rejection (Fierce)
• Looking to expand Pyrukynd label, Agios treks toward PhIII in sickle cell disease (Endpoints)
• Shareholders elect director’s romantic partner to Biogen’s board (STAT)
• Lonza, Vertex to build a new cell therapy manufacturing facility for the biotech’s type 1 diabetes therapies (Endpoints)
• Erytech’s merger with Pherecydes reaches the finish line after contentious few months (Fierce)
• Shionogi takes antibiotic maker under its wing in $100M cash buyout (Endpoints)
• Avalo fails asthma PhII with lead candidate, shares crater (Endpoints)
• Invivyd, FDA agree on steps to emergency approval for COVID monoclonal antibody (Fierce)
• FibroGen reports third PhIII failure in two months, this time in idiopathic pulmonary fibrosis (Endpoints)
• The secret to designing protein drugs with AI? Generate believes it's cryo-EM at unprecedented scale (Endpoints)
• MoonLake's PhII data on skin disease set it up against Cosentyx, UCB and others in IL-17 field (Endpoints)

• ADA: Abbott pushes for widespread CGM use in Type 2 diabetes with WeightWatchers, ADA collabs (Fierce)
• Medtronic links 780G insulin pump to benefits in kids as it works to grow sales (MedtechDive) (Fierce)
• ADA: Gelesis study data position stomach-filling capsule as alternative to GLP-1s for weight loss (Fierce)
• Conformis stock soars on buyout deal from fellow implant maker restor3d (Fierce)
• Teleflex, and Arrow International, Recall ARROW Endurance Extended Dwell Peripheral Catheter System for Risk of Catheter Separation and Leakage (FDA)
• Rare FDA Move Shows Stance On Remote Monitoring Devices (Law360)

• Biden directs HHS to boost contraception access, a year after Dobbs decision (STAT)
• McKinsey Nears Opioid MDL Deal With Tribes, Insurance Plans (Law360)